Product Details
| Alternative Name: | TRAIL receptor 3, DcR1, Death Receptor 1, TRID, CD263, TNFRSF 10C, TNF-related apoptosis-inducing ligand receptor 3, Tumor necrosis factor receptor superfamily member 10C |
| |
| Clone: | HS301 |
| |
| Host: | Mouse |
| |
| Isotype: | IgG1 |
| |
| Immunogen: | Recombinant human TRAIL-R3. |
| |
| UniProt ID: | O14798 |
| |
| Gene/Protein Identifier: | 8794 (Entrez GeneID) |
| |
| Species reactivity: | Human
|
| |
| Crossreactivity: | Does not cross-react with human TRAIL-R1, -R2 or -R4. |
| |
| Applications: | Flow Cytometry, ICC
|
| |
| Application Notes: | For Western blot of whole cell lysate, use PAb to TRAIL-R3 (human) (from goat) (Prod. No. ALX-210-744). |
| |
| Formulation: | Liquid. In PBS containing 0.05% sodium azide. |
| |
| Handling: | Avoid freeze/thaw cycles. |
| |
| Shipping: | Blue Ice |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Figure: Receptor specificity of the monoclonal antibodies HS301 for TRAIL-R3 (Prod. No.
ALX-804-344).
Method: CV1/EBNA cells were transfected either with the empty expression vector pCDNA3 (vector control) or pCDNA3 encoding TRAIL-R1 to TRAIL-R4. Two days after transfection 1 x 10
6 cells were stained with mAb HS301 against TRAIL-R3 (Prod. No.
ALX- 804-344).
All primary antibodies were used at 10 µg/ml, followed by biotinylated goat anti-mouse IgG1 and streptavidin-PE. Transfection efficiency was about 50% in all individual transfections.
Note: HS301 also detects endogenous cell surface expressed TRAIL-R3 in FACS (unpublished data). In most cell types endogenous TRAIL-R3 appears to be mainly expressed intracellular, why cell permeabilization may be required to obtain a signal by FACS."
Please mouse over
Product Literature References
Decreased affinity of recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) D269H/E195R to osteoprotegerin (OPG) overcomes TRAIL resistance mediated by the bone microenvironment: M.C. Bosman, et al.; J. Biol. Chem.
289, 1071 (2014),
Abstract;
Full Text
Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sezary syndrome T-cells associated with impaired death receptor and FLICE-inhibitory protein expression: E. Contassot, et al.; Blood
111, 4780 (2008),
Abstract;
TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window: R. Koschny, et al.; Hepatology
45, 649 (2007),
Abstract;
cFLIPL inhibits tumor necrosis factor-related apoptosis-inducing ligand-mediated NF-kappaB activation at the death-inducing signaling complex in human keratinocytes: T. Wachter, et al.; J. Biol. Chem.
279, 52824 (2004),
Abstract;
Full Text
Enhanced caspase-8 recruitment to and activation at the DISC is critical for sensitisation of human hepatocellular carcinoma cells to TRAIL-induced apoptosis by chemotherapeutic drugs: T.M. Ganten, et al.; Cell Death Differ.
11 Suppl 1, S86 (2004),
Abstract;
TRAIL regulates normal erythroid maturation through an ERK-dependent pathway: P. Secchiero, et al.; Blood
103, 517 (2004),
Abstract;
TNF-Related Apoptosis-Inducing Ligand Mediates Tumoricidal Activity of Human Monocytes Stimulated by Newcastle Disease Virus: B. Washburn, et al.; J. Immunol.
170, 1814 (2003),
Abstract;
Related Products
